605 related articles for article (PubMed ID: 34488602)
1. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.
Rawat P; Sehar U; Bisht J; Selman A; Culberson J; Reddy PH
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361631
[TBL] [Abstract][Full Text] [Related]
3. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
[TBL] [Abstract][Full Text] [Related]
4. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
Stancu IC; Ferraiolo M; Terwel D; Dewachter I
Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.
Khanna MR; Kovalevich J; Lee VM; Trojanowski JQ; Brunden KR
Alzheimers Dement; 2016 Oct; 12(10):1051-1065. PubMed ID: 27751442
[TBL] [Abstract][Full Text] [Related]
6. Targeting tau: Clinical trials and novel therapeutic approaches.
VandeVrede L; Boxer AL; Polydoro M
Neurosci Lett; 2020 Jul; 731():134919. PubMed ID: 32380145
[TBL] [Abstract][Full Text] [Related]
7. Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies.
Pires G; McElligott S; Drusinsky S; Halliday G; Potier MC; Wisniewski T; Drummond E
Acta Neuropathol Commun; 2019 Dec; 7(1):195. PubMed ID: 31796108
[TBL] [Abstract][Full Text] [Related]
8. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies.
Vingtdeux V; Davies P; Dickson DW; Marambaud P
Acta Neuropathol; 2011 Mar; 121(3):337-49. PubMed ID: 20957377
[TBL] [Abstract][Full Text] [Related]
9. Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.
Gibbons GS; Banks RA; Kim B; Changolkar L; Riddle DM; Leight SN; Irwin DJ; Trojanowski JQ; Lee VMY
J Neuropathol Exp Neurol; 2018 Mar; 77(3):216-228. PubMed ID: 29415231
[TBL] [Abstract][Full Text] [Related]
10. Tau Proteins and Tauopathies in Alzheimer's Disease.
Chong FP; Ng KY; Koh RY; Chye SM
Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
[TBL] [Abstract][Full Text] [Related]
11. [Neuroprotective treatment of tauopathies].
Respondek G; Krey L; Huber M; Pflugrad H; Wegner F; Höglinger GU
Nervenarzt; 2021 Dec; 92(12):1227-1238. PubMed ID: 34652482
[TBL] [Abstract][Full Text] [Related]
12. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
13. Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies.
Xia Y; Prokop S; Gorion KM; Kim JD; Sorrentino ZA; Bell BM; Manaois AN; Chakrabarty P; Davies P; Giasson BI
Acta Neuropathol Commun; 2020 Jun; 8(1):88. PubMed ID: 32571418
[TBL] [Abstract][Full Text] [Related]
14. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
Jangampalli Adi P; Reddy PH
Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
[TBL] [Abstract][Full Text] [Related]
16. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
Ferrer I; Gomez-Isla T; Puig B; Freixes M; Ribé E; Dalfó E; Avila J
Curr Alzheimer Res; 2005 Jan; 2(1):3-18. PubMed ID: 15977985
[TBL] [Abstract][Full Text] [Related]
17. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
18. Tau pathology and future therapeutics.
Gozes I
Curr Alzheimer Res; 2010 Dec; 7(8):685-96. PubMed ID: 20678069
[TBL] [Abstract][Full Text] [Related]
19. Targeting tau protein in Alzheimer's disease.
Gong CX; Grundke-Iqbal I; Iqbal K
Drugs Aging; 2010 May; 27(5):351-65. PubMed ID: 20450234
[TBL] [Abstract][Full Text] [Related]
20. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
Brunden KR; Trojanowski JQ; Lee VM
Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
